Compare BHR & DERM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BHR | DERM |
|---|---|---|
| Founded | 2013 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 159.3M | 135.3M |
| IPO Year | N/A | 2021 |
| Metric | BHR | DERM |
|---|---|---|
| Price | $2.10 | $6.10 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $12.67 |
| AVG Volume (30 Days) | ★ 447.4K | 196.4K |
| Earning Date | 05-06-2026 | 05-13-2026 |
| Dividend Yield | ★ 8.47% | N/A |
| EPS Growth | N/A | ★ 34.72 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $61,858,000.00 |
| Revenue This Year | N/A | $39.72 |
| Revenue Next Year | N/A | $63.24 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 10.20 |
| 52 Week Low | $2.00 | $4.31 |
| 52 Week High | $3.19 | $9.56 |
| Indicator | BHR | DERM |
|---|---|---|
| Relative Strength Index (RSI) | 29.84 | 52.21 |
| Support Level | N/A | $5.79 |
| Resistance Level | $2.61 | $6.59 |
| Average True Range (ATR) | 0.13 | 0.30 |
| MACD | -0.05 | -0.03 |
| Stochastic Oscillator | 11.54 | 44.70 |
Braemar Hotels & Resorts Inc is a real estate investment trust company that invests in high revenue per available room, or RevPAR, luxury hotels and resorts. The firm operates in various U.S. states such as California, Texas, Washington, Philadelphia, Florida, and Illinois as well as Washington, D.C. and St. Thomas, U.S. Virgin Islands. The company operates through its direct hotel investment segment of the hotel lodging industry. Its revenue streams include rooms, food and beverage, and other. The firm's hotels operate under various brands, such as Marriott, Hilton, Courtyard, and, among others.
Journey Medical Corp is a commercial-stage pharmaceutical company that focuses on the selling and marketing of U.S. Food and Drug Administration (FDA) approved prescription pharmaceutical products for the treatment of dermatological conditions. Its current product portfolio includes FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. The company views its operations and manages its business in one segment, which reflects products for the treatment of dermatological conditions. The dermatological segment derives revenues from the sale of branded and authorized general prescription products that treat certain dermatological conditions.